Using PET imaging to improve radiation therapy for high-risk meningiomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of somatostatin receptor PET imaging to guide the escalation of radiation therapy doses in patients with high-risk meningiomas. By utilizing PET imaging, the study aims to better define the radiation treatment volume compared to standard MRI methods. The goal is to determine if higher doses of radiation, tailored using PET imaging, can be safely administered and lead to improved progression-free survival rates. Participants will receive radiation treatment based on the findings from their PET scans.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 16 years;
* Ability to express appropriate informed consent to treatment;
* Diagnosis of grade III meningioma (regardless of presence of residual) or diagnosis of recurrence of grade II meningioma (regardless of presence of residual) or first diagnosis of grade II meningioma with presence of residual;
* In case of recurrence, confirmation can be either histological or radiological;
* Not previous brain-level radiotherapy;
* Performance status: ECOG=0-2.

Exclusion Criteria:

* Refusal to radiation treatment (i.e., absence of signed informed consent);
* Other concomitant oncologic therapies
* Current pregnancy;
* Grade I meningiomas or Grade II meningiomas if operated on at first diagnosis with radical resection;
* Inability to perform MRI with MoC or PET.

Where it's running

• Centro di Riferimento Oncologico di Aviano (CRO)
  Aviano, Pordenone, Italy Recruiting

Study contacts

• Principal investigator: Lorenzo Vinante — Centro di Riferimento Oncologico di Aviano (CRO)
• Study coordinator: Lorenzo Vinante
• Email: lorenzo.vinante@cro.it
• Phone: 0434 659855

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination therapy with IN10018 and dalpiciclib for progressive meningioma

  This phase 1 study tests whether taking IN10018 with dalpiciclib is safe and tolerable in adults with growing meningiomas to see if the combo can help control the tumor.

  Recruiting Phase 1 Capital Medical University · Beijing, Beijing Municipality and 1 other locations · NCT07652762

• JZP3507 (ONC206) for recurrent Grade 2/3 meningioma

  A pill-based therapy (JZP3507) is being tested to see if it can help adults with recurrent grade 2 or 3 meningioma who have not benefited from standard treatments.

  Recruiting at 6 sites Phase 2 Jazz Pharmaceuticals · San Francisco, California and 7 other locations · NCT07533942

• Panitumumab-IRDye800 for guiding brain tumor surgery

  A tiny dose of panitumumab-IRDye800 is tested to see if it helps visualize brain tumors during surgery in adults.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07493447

• Zanzalintinib for recurrent or progressive meningioma

  This trial tests whether zanzalintinib can help people whose meningioma has come back or kept growing after standard treatments.

  Recruiting at 20 sites Phase 2 Exelixis · Birmingham, Alabama and 19 other locations · NCT07428616

• Meningioma: How social factors and personal risks relate to health outcomes

  This study tests whether social and personal risk factors help explain differences in health outcomes for adults with meningioma.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07418775

• Skin closure after brain tumor surgery: running absorbable versus interrupted non-absorbable sutures

  This will test whether absorbable running intradermal sutures or non-absorbable interrupted transdermal sutures produce better wound healing after craniotomy in adults with supratentorial brain tumors.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07413796

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.